{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P01138",
      "entity_text" : "NGF",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ03457",
      "entity_text" : "Tanezumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Tanezumab, a monoclonal antibody against beta-NGF receptor tyrosine kinase (TrkA), inhibits NGF action and reduces pain in patients.",
  "reading_complete" : "2020-08-04T23:17:32Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T23:15:30Z",
  "trigger" : "inhibits",
  "evidence" : [ "Tanezumab, a monoclonal antibody against beta-NGF receptor tyrosine kinase (TrkA), inhibits NGF" ],
  "pmc_id" : "4303902",
  "score" : 0
}